Our analysis, although limited in scope to a single MYCN-amplified cell line, identified many elevated phosphopeptides from proteins within the neuroblastoma phosphoproteome that could be targeted therapeutically to inhibit tumor growth. The gene discussed is MYCN; the disease is neuroblastoma.